

Jose Maria Lopez-Picazo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6613430/publications.pdf>

Version: 2024-02-01

67
papers

1,851
citations

279487

23
h-index

264894

42
g-index

68
all docs

68
docs citations

68
times ranked

3466
citing authors

#	ARTICLE	IF	CITATIONS
1	Serum Interleukin-8 Reflects Tumor Burden and Treatment Response across Malignancies of Multiple Tissue Origins. <i>Clinical Cancer Research</i> , 2014, 20, 5697-5707.	3.2	200
2	Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes. <i>British Journal of Cancer</i> , 2009, 100, 1111-1119.	2.9	183
3	ERK1/2 is activated in non-small-cell lung cancer and associated with advanced tumours. <i>British Journal of Cancer</i> , 2004, 90, 1047-1052.	2.9	166
4	Front-Line Paclitaxel/Cisplatin-Based Chemotherapy in Brain Metastases from Non-Small-Cell Lung Cancer. <i>Oncology</i> , 2003, 64, 28-35.	0.9	126
5	Mitogen-Activated Protein Kinase Phosphatase-1 Is Overexpressed in Non-Small Cell Lung Cancer and Is an Independent Predictor of Outcome in Patients. <i>Clinical Cancer Research</i> , 2004, 10, 3639-3649.	3.2	125
6	Identification of Tissue microRNAs Predictive of Sunitinib Activity in Patients with Metastatic Renal Cell Carcinoma. <i>PLoS ONE</i> , 2014, 9, e86263.	1.1	76
7	Role of [18F]FDG PET in prediction of KRAS and EGFR mutation status in patients with advanced non-small-cell lung cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 2058-2065.	3.3	75
8	Complement activation mediates cetuximab inhibition of non-small cell lung cancer tumor growth in vivo. <i>Molecular Cancer</i> , 2010, 9, 139.	7.9	69
9	An imbalance in Akt/mTOR is involved in the apoptotic and acantholytic processes in a mouse model of pemphigus vulgaris. <i>Experimental Dermatology</i> , 2009, 18, 771-780.	1.4	65
10	Complement C5a induces the formation of neutrophil extracellular traps by myeloid-derived suppressor cells to promote metastasis. <i>Cancer Letters</i> , 2022, 529, 70-84.	3.2	51
11	CT-guided permanent brachytherapy for patients with medically inoperable early-stage non-small cell lung cancer (NSCLC). <i>Lung Cancer</i> , 2008, 61, 209-213.	0.9	46
12	The Oncoprotein SF2/ASF Promotes Non-Small Cell Lung Cancer Survival by Enhancing Survivin Expression. <i>Clinical Cancer Research</i> , 2010, 16, 4113-4125.	3.2	46
13	Id1 and Id3 co-expression correlates with clinical outcome in stage III-N2 non-small cell lung cancer patients treated with definitive chemoradiotherapy. <i>Journal of Translational Medicine</i> , 2013, 11, 13.	1.8	38
14	Efficacy of nintedanib and docetaxel in patients with advanced lung adenocarcinoma treated with first-line chemotherapy and second-line immunotherapy in the nintedanib NPU program. <i>Clinical and Translational Oncology</i> , 2019, 21, 1270-1279.	1.2	38
15	Total and mutated EGFR quantification in cell-free DNA from non-small cell lung cancer patients detects tumor heterogeneity and presents prognostic value. <i>Tumor Biology</i> , 2016, 37, 13687-13694.	0.8	37
16	Acneiform lesions secondary to ZD1839, an inhibitor of the epidermal growth factor receptor. <i>Clinical and Experimental Dermatology</i> , 2004, 29, 138-140.	0.6	36
17	CD8 T Cell Priming in the Presence of IFN- γ Renders CTLs with Improved Responsiveness to Homeostatic Cytokines and Recall Antigens: Important Traits for Adoptive T Cell Therapy. <i>Journal of Immunology</i> , 2012, 189, 3299-3310.	0.4	36
18	The inhibitor of differentiation-1 (Id1) enables lung cancer liver colonization through activation of an EMT program in tumor cells and establishment of the pre-metastatic niche. <i>Cancer Letters</i> , 2017, 402, 43-51.	3.2	36

#	ARTICLE	IF	CITATIONS
19	Bringing Model-Based Prediction to Oncology Clinical Practice: A Review of Pharmacometrics Principles and Applications. <i>Oncologist</i> , 2016, 21, 220-232.	1.9	35
20	Phase II study of pemetrexed in combination with cisplatin and cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck. <i>European Journal of Cancer</i> , 2013, 49, 2877-2883.	1.3	30
21	A Population Pharmacodynamic Model for Lactate Dehydrogenase and Neuron Specific Enolase to Predict Tumor Progression in Small Cell Lung Cancer Patients. <i>AAPS Journal</i> , 2014, 16, 609-619.	2.2	26
22	Development of a novel splice array platform and its application in the identification of alternative splice variants in lung cancer. <i>BMC Genomics</i> , 2010, 11, 352.	1.2	25
23	Toxic Epidermal Necrolysis Related to Pemetrexed and Carboplatin with Vitamin B12 and Folic Acid Supplementation for Advanced Non-Small Cell Lung Cancer. <i>Onkologie</i> , 2009, 32, 580-584.	1.1	24
24	Predictive factors for radiation-induced pulmonary toxicity after three-dimensional conformal chemoradiation in locally advanced non-small-cell lung cancer. <i>Clinical and Translational Oncology</i> , 2007, 9, 596-602.	1.2	21
25	Dosimetric analysis of the patterns of local failure observed in patients with locally advanced non-small cell lung cancer treated with neoadjuvant chemotherapy and concurrent conformal (3D-CRT) chemoradiation. <i>Radiotherapy and Oncology</i> , 2008, 88, 342-350.	0.3	20
26	Percutaneous CT-guided 103Pd implantation for the medically inoperable patient with T1N0M0 non-small cell lung cancer: A case report. <i>Brachytherapy</i> , 2004, 3, 179-181.	0.2	15
27	Randomized Crossover Pharmacokinetic Evaluation of Subcutaneous Versus Intravenous Granisetron in Cancer Patients Treated with Platinum-Based Chemotherapy. <i>Oncologist</i> , 2007, 12, 1151-1155.	1.9	15
28	EUELC project: a multi-centre, multipurpose study to investigate early stage NSCLC, and to establish a biobank for ongoing collaboration. <i>European Respiratory Journal</i> , 2009, 34, 1477-1486.	3.1	15
29	Functional expression of CD137 (4-1BB) on T helper follicular cells. <i>Oncolmmunology</i> , 2015, 4, e1054597.	2.1	15
30	Hypomagnesemia as a possible explanation behind episodes of severe pain in cancer patients receiving palliative care. <i>Supportive Care in Cancer</i> , 2013, 21, 649-652.	1.0	14
31	Concomitant Cisplatin, Paclitaxel, and Hyperfractionated Radiotherapy in Locally Advanced Head and Neck Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2010, 33, 137-143.	0.6	14
32	Fibrosing cholestatic hepatitis following cytotoxic chemotherapy for small-cell lung cancer. <i>World Journal of Gastroenterology</i> , 2009, 15, 2290.	1.4	14
33	Activity of Gefitinib in Central Nervous System Metastases in Patients with Non-Small-Cell Lung Cancer: Two Case Reports and a Review of the Literature. <i>Clinical Lung Cancer</i> , 2005, 7, 138-140.	1.1	12
34	Induction Platinum-Based Chemotherapy Followed by Radical Hyperfractionated Radiotherapy With Concurrent Chemotherapy in the Treatment of Locally Advanced Non-Small-Cell Carcinoma of the Lung. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1999, 22, 203-208.	0.6	12
35	Transoesophageal endoscopic-ultrasonography-guided 125I permanent brachytherapy for unresectable mediastinal lymphadenopathy. <i>Lancet Oncology</i> , The, 2006, 7, 781-783.	5.1	11
36	Genomic characterization of individuals presenting extreme phenotypes of high and low risk to develop tobacco-induced lung cancer. <i>Cancer Medicine</i> , 2018, 7, 3474-3483.	1.3	11

#	ARTICLE	IF	CITATIONS
37	Adult onset Still's disease after first cycle of pemetrexed and gemcitabine for non-small cell lung cancer. <i>Lung Cancer</i> , 2009, 64, 124-126.	0.9	9
38	Early Prediction of Disease Progression in Small Cell Lung Cancer: Toward Model-Based Personalized Medicine in Oncology. <i>Cancer Research</i> , 2015, 75, 2416-2425.	0.4	9
39	Factors influencing the use of thromboprophylaxis in cancer outpatients in clinical practice: A prospective study. <i>Thrombosis Research</i> , 2015, 136, 1145-1148.	0.8	9
40	Randomized Pharmacokinetic Study Comparing Subcutaneous and Intravenous Palonosetron in Cancer Patients Treated with Platinum Based Chemotherapy. <i>PLoS ONE</i> , 2014, 9, e89747.	1.1	8
41	Assessment of the value of confirming responses in clinical trials in oncology. <i>European Journal of Cancer</i> , 2005, 41, 1528-1532.	1.3	7
42	Isolated dysphagia due to paraneoplastic myasthenic syndrome with anti-P/Q-type voltage-gated calcium-channel and anti-acetylcholine receptor antibodies. <i>Neuromuscular Disorders</i> , 2011, 21, 126-128.	0.3	7
43	The multimodal management of locally advanced N2 non-small cell lung cancer: is there a role for surgical resection? A single institution's experience. <i>Clinical and Translational Oncology</i> , 2012, 14, 835-841.	1.2	6
44	Endovascular treatment of malignant superior vena cava syndrome secondary to lung cancer. <i>Hospital Practice (1995)</i> , 2017, 45, 70-75.	0.5	5
45	Paclitaxel, Cisplatin, and Vinorelbine Combination Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2004, 27, 299-303.	0.6	4
46	Role of Surgery in a Multidisciplinary Approach to Superior Sulcus Tumors (SST): Morbidity and Prognostic Factors for Long-Term Success after Resection. <i>Thoracic and Cardiovascular Surgeon</i> , 2009, 57, 353-357.	0.4	4
47	Radiation Therapy After High-Dose Chemotherapy With Peripheral Blood Stem Cell Support for High-Risk Breast Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2002, 25, 347-353.	0.6	3
48	Preliminary experience with intensity modulated radiation therapy for abdominopelvic tumor sites: a comparison with 3D radiotherapy plans. <i>Clinical and Translational Oncology</i> , 2004, 6, 415-423.	1.2	1
49	Identification through genome-wide association study (GWAS) of single nucleotide polymorphisms (SNPs) associated with extreme phenotypes of tobacco-induced non-small cell lung cancer (NSCLC) risk. <i>Journal of Clinical Oncology</i> , 2014, 32, 11046-11046.	0.8	1
50	Pulmonary embolism after local urokinase instillation in a Hickman catheter. <i>Bone Marrow Transplantation</i> , 2001, 28, 112-113.	1.3	0
51	79PD THE ROLE OF SURGICAL RESECTION IN THE MULTIMODAL MANAGEMENT OF LOCALLY ADVANCED N2 NON-SMALL CELL LUNG CANCER. A SINGLE INSTITUTION'S EXPERIENCE. <i>Lung Cancer</i> , 2011, 71, S40.	0.9	0
52	Targeting the Expression of the Inhibitor of Differentiation (Id) Genes in Tumor Microenvironment (Tme) and Tumor Cells is Crucial in the Prevention of Liver Metastasis (Lm) from Lung Cancer. <i>Annals of Oncology</i> , 2014, 25, iv63.	0.6	0
53	Serum Interleukin-8 Reflects Tumor Burden and Treatment Response Across Malignancies of Multiple Tissue Origins. <i>Annals of Oncology</i> , 2014, 25, iv84.	0.6	0
54	Phase Ii Study with Immunotherapy with Dendritic Cells (Dc) Combined with Intratumoral Hiltonol in Patients with Advanced Cancer. <i>Annals of Oncology</i> , 2014, 25, iv371.	0.6	0

#	ARTICLE	IF	CITATIONS
55	Inhibitor of Differentiation-1 (Id1) and Id3 Expression Correlates with Epithelial-Mesenchymal Transition (Emt)-Related Proteins (Emtrp) in Non-Small Cell Lung Carcinoma (Nslc). Annals of Oncology, 2014, 25, iv565.	0.6	0
56	Genome Wide Association Study (Gwas) for Identification of Single Nucleotide Polymorphisms (Snps) Associated with Individuals Presenting Extreme Phenotypes of Tobacco Induced Non-Small Cell Lung Cancer (Nslc) Risk. Annals of Oncology, 2014, 25, iv548.	0.6	0
57	Id1 and Id3 genes confer poor prognosis in KRAS-mutant (KM) lung adenocarcinoma (LA) patients. Gene silencing reduces metastatic rate to the liver and increases survival. Annals of Oncology, 2016, 27, vi440.	0.6	0
58	Differences in Venous Thromboembolism Prevention and Outcome between Hospitalized Patients with Solid and Hematologic Malignancies. TH Open, 2019, 03, e153-e156.	0.7	0
59	Resultados a medio y largo plazo de la utilizaci3n de videotoracosopia en la cirug3a de resecci3n de las met3stasis pulmonares. Anales Del Sistema Sanitario De Navarra, 0, 28, .	0.2	0
60	Abstract 3103: Survivin expression is enhanced by the oncoprotein SF2/ASF in non-small cell lung cancer. , 2010, , .		0
61	Safety and efficacy of maintenance therapy (MT) with a nonspecific cytochrome-P 17 inhibitor (CYP17i) after response/stabilization to docetaxel in metastatic castration-resistant prostate cancer (mCRPC) patients.. Journal of Clinical Oncology, 2012, 30, 145-145.	0.8	0
62	EGFR-activating mutations and treatment with tyrosine-kinase inhibitors (TKI) to revert poor-prognosis (PP) associated with liver metastases (LM) in stage IV non-small cell lung cancer (NSCLC) patients (pts).. Journal of Clinical Oncology, 2013, 31, e19106-e19106.	0.8	0
63	Adrenalectomy for low-tumor-burden metastatic lung cancer: Results of a single institution experience.. Journal of Clinical Oncology, 2013, 31, e19114-e19114.	0.8	0
64	Phase II study with immunotherapy with dendritic cells (DC) and intratumoral hiltonol in patients with advanced solid tumors.. Journal of Clinical Oncology, 2014, 32, TPS3113-TPS3113.	0.8	0
65	Serum interleukin-8 and its relationship to tumor burden and treatment response across malignancies of multiple tissue origins.. Journal of Clinical Oncology, 2014, 32, e22135-e22135.	0.8	0
66	Abstract 1996: Inhibitor of differentiation-1 (Id1) expression deficiency in the tumor microenvironment impairs experimental hepatic metastasis of lung cancer. , 2014, , .		0
67	Familial clustering of lung cancer (LC) cases in a south European population (sEp).. Journal of Clinical Oncology, 2015, 33, e12621-e12621.	0.8	0